ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Chronic Obstructive Pulmonary Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-1H12369
Home | Market Reports | Health| Health Conditions
Global Chronic Obstructive Pulmonary Disease Drugs Industry Research Report Growth Trends and Competitive Analysis 2022 2028
BUY CHAPTERS

Chronic Obstructive Pulmonary Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-1H12369
Report
September 2024
Pages:121
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Boehringer Ingelheim
GSK
Novartis
Teva Pharmaceuticals
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
ASMACURE
Astellas Pharma
Biomarck Pharmaceuticals

Chronic Obstructive Pulmonary Disease Drugs - Market Size

The global market for Chronic Obstructive Pulmonary Disease Drugs was estimated to be worth US$ 22910 million in 2023 and is forecast to a readjusted size of US$ 32360 million by 2030 with a CAGR of 5.0% during the forecast period 2024-2030

Chronic Obstructive Pulmonary Disease Drugs - Market

Chronic Obstructive Pulmonary Disease Drugs - Market

Chronic obstructive pulmonary disease ( COPD ) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disease Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Chronic Obstructive Pulmonary Disease Drugs by region & country, by Type, and by Application.
The Chronic Obstructive Pulmonary Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disease Drugs.
Market Segmentation

Scope of Chronic Obstructive Pulmonary Disease Drugs - Market Report

Report Metric Details
Report Name Chronic Obstructive Pulmonary Disease Drugs - Market
Forecasted market size in 2030 US$ 32360 million
CAGR 5.0%
Forecasted years 2024 - 2030
Segment by Type:
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva Pharmaceuticals, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Chronic Obstructive Pulmonary Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Chronic Obstructive Pulmonary Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Chronic Obstructive Pulmonary Disease Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Chronic Obstructive Pulmonary Disease Drugs - Market size in 2030?

Ans: The Chronic Obstructive Pulmonary Disease Drugs - Market size in 2030 will be US$ 32360 million.

Who are the main players in the Chronic Obstructive Pulmonary Disease Drugs - Market report?

Ans: The main players in the Chronic Obstructive Pulmonary Disease Drugs - Market are AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva Pharmaceuticals, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals

What are the Application segmentation covered in the Chronic Obstructive Pulmonary Disease Drugs - Market report?

Ans: The Applications covered in the Chronic Obstructive Pulmonary Disease Drugs - Market report are Emphysema, Chronic Bronchitis, Refractory Asthma, Others

What are the Type segmentation covered in the Chronic Obstructive Pulmonary Disease Drugs - Market report?

Ans: The Types covered in the Chronic Obstructive Pulmonary Disease Drugs - Market report are Inhalers, Nebulizers

Recommended Reports

COPD and Lung Drugs

Pulmonary Diseases Therapy

Respiratory and Related

1 Market Overview
1.1 Chronic Obstructive Pulmonary Disease Drugs Product Introduction
1.2 Global Chronic Obstructive Pulmonary Disease Drugs Market Size Forecast
1.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030)
1.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume (2019-2030)
1.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Price (2019-2030)
1.3 Chronic Obstructive Pulmonary Disease Drugs Market Trends & Drivers
1.3.1 Chronic Obstructive Pulmonary Disease Drugs Industry Trends
1.3.2 Chronic Obstructive Pulmonary Disease Drugs Market Drivers & Opportunity
1.3.3 Chronic Obstructive Pulmonary Disease Drugs Market Challenges
1.3.4 Chronic Obstructive Pulmonary Disease Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Chronic Obstructive Pulmonary Disease Drugs Players Revenue Ranking (2023)
2.2 Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2019-2024)
2.3 Global Chronic Obstructive Pulmonary Disease Drugs Players Sales Volume Ranking (2023)
2.4 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Chronic Obstructive Pulmonary Disease Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Chronic Obstructive Pulmonary Disease Drugs
2.9 Chronic Obstructive Pulmonary Disease Drugs Market Competitive Analysis
2.9.1 Chronic Obstructive Pulmonary Disease Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Chronic Obstructive Pulmonary Disease Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disease Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Inhalers
3.1.2 Nebulizers
3.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type
3.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Type
3.3.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Chronic Obstructive Pulmonary Disease Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Emphysema
4.1.2 Chronic Bronchitis
4.1.3 Refractory Asthma
4.1.4 Others
4.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application
4.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Application
4.3.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Chronic Obstructive Pulmonary Disease Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region
5.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (2019-2024)
5.1.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (2025-2030)
5.1.4 Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region
5.2.1 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Chronic Obstructive Pulmonary Disease Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
5.4.2 North America Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
5.5.2 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
5.7.2 South America Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value
6.2.1 Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.3.2 United States Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.4.2 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.5.2 China Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.6.2 Japan Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.7.2 South Korea Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019-2030
6.9.2 India Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Information
7.1.2 AstraZeneca Introduction and Business Overview
7.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.1.5 AstraZeneca Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Introduction and Business Overview
7.2.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.2.5 Boehringer Ingelheim Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 GSK Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.3.5 GSK Recent Development
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Introduction and Business Overview
7.4.3 Novartis Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Novartis Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.4.5 Novartis Recent Development
7.5 Teva Pharmaceuticals
7.5.1 Teva Pharmaceuticals Company Information
7.5.2 Teva Pharmaceuticals Introduction and Business Overview
7.5.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.5.5 Teva Pharmaceuticals Recent Development
7.6 Ache Laboratorios Farmaceuticos
7.6.1 Ache Laboratorios Farmaceuticos Company Information
7.6.2 Ache Laboratorios Farmaceuticos Introduction and Business Overview
7.6.3 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.6.5 Ache Laboratorios Farmaceuticos Recent Development
7.7 Almirall
7.7.1 Almirall Company Information
7.7.2 Almirall Introduction and Business Overview
7.7.3 Almirall Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Almirall Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.7.5 Almirall Recent Development
7.8 Aquinox Pharmaceuticals
7.8.1 Aquinox Pharmaceuticals Company Information
7.8.2 Aquinox Pharmaceuticals Introduction and Business Overview
7.8.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.8.5 Aquinox Pharmaceuticals Recent Development
7.9 Ario Pharma
7.9.1 Ario Pharma Company Information
7.9.2 Ario Pharma Introduction and Business Overview
7.9.3 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.9.5 Ario Pharma Recent Development
7.10 Asmacure
7.10.1 Asmacure Company Information
7.10.2 Asmacure Introduction and Business Overview
7.10.3 Asmacure Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Asmacure Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.10.5 Asmacure Recent Development
7.11 Astellas Pharma
7.11.1 Astellas Pharma Company Information
7.11.2 Astellas Pharma Introduction and Business Overview
7.11.3 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.11.5 Astellas Pharma Recent Development
7.12 BioMarck Pharmaceuticals
7.12.1 BioMarck Pharmaceuticals Company Information
7.12.2 BioMarck Pharmaceuticals Introduction and Business Overview
7.12.3 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
7.12.4 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Offerings
7.12.5 BioMarck Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Chronic Obstructive Pulmonary Disease Drugs Industrial Chain
8.2 Chronic Obstructive Pulmonary Disease Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Chronic Obstructive Pulmonary Disease Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Chronic Obstructive Pulmonary Disease Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Boehringer Ingelheim
GSK
Novartis
Teva Pharmaceuticals
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
ASMACURE
Astellas Pharma
Biomarck Pharmaceuticals
List of Tables
    Table 1. Chronic Obstructive Pulmonary Disease Drugs Market Trends
    Table 2. Chronic Obstructive Pulmonary Disease Drugs Market Drivers & Opportunity
    Table 3. Chronic Obstructive Pulmonary Disease Drugs Market Challenges
    Table 4. Chronic Obstructive Pulmonary Disease Drugs Market Restraints
    Table 5. Global Chronic Obstructive Pulmonary Disease Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Chronic Obstructive Pulmonary Disease Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Chronic Obstructive Pulmonary Disease Drugs Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Chronic Obstructive Pulmonary Disease Drugs
    Table 13. Global Chronic Obstructive Pulmonary Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disease Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Chronic Obstructive Pulmonary Disease Drugs Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Chronic Obstructive Pulmonary Disease Drugs Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Chronic Obstructive Pulmonary Disease Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Chronic Obstructive Pulmonary Disease Drugs Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Chronic Obstructive Pulmonary Disease Drugs Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Chronic Obstructive Pulmonary Disease Drugs Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Chronic Obstructive Pulmonary Disease Drugs Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Volume, (2025-2030) & (K Units)
    Table 57. AstraZeneca Company Information
    Table 58. AstraZeneca Introduction and Business Overview
    Table 59. AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 61. AstraZeneca Recent Development
    Table 62. Boehringer Ingelheim Company Information
    Table 63. Boehringer Ingelheim Introduction and Business Overview
    Table 64. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 66. Boehringer Ingelheim Recent Development
    Table 67. GSK Company Information
    Table 68. GSK Introduction and Business Overview
    Table 69. GSK Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. GSK Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 71. GSK Recent Development
    Table 72. Novartis Company Information
    Table 73. Novartis Introduction and Business Overview
    Table 74. Novartis Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Novartis Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 76. Novartis Recent Development
    Table 77. Teva Pharmaceuticals Company Information
    Table 78. Teva Pharmaceuticals Introduction and Business Overview
    Table 79. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 81. Teva Pharmaceuticals Recent Development
    Table 82. Ache Laboratorios Farmaceuticos Company Information
    Table 83. Ache Laboratorios Farmaceuticos Introduction and Business Overview
    Table 84. Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 86. Ache Laboratorios Farmaceuticos Recent Development
    Table 87. Almirall Company Information
    Table 88. Almirall Introduction and Business Overview
    Table 89. Almirall Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Almirall Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 91. Almirall Recent Development
    Table 92. Aquinox Pharmaceuticals Company Information
    Table 93. Aquinox Pharmaceuticals Introduction and Business Overview
    Table 94. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 96. Aquinox Pharmaceuticals Recent Development
    Table 97. Ario Pharma Company Information
    Table 98. Ario Pharma Introduction and Business Overview
    Table 99. Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 101. Ario Pharma Recent Development
    Table 102. Asmacure Company Information
    Table 103. Asmacure Introduction and Business Overview
    Table 104. Asmacure Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Asmacure Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 106. Asmacure Recent Development
    Table 107. Astellas Pharma Company Information
    Table 108. Astellas Pharma Introduction and Business Overview
    Table 109. Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 110. Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 111. Astellas Pharma Recent Development
    Table 112. BioMarck Pharmaceuticals Company Information
    Table 113. BioMarck Pharmaceuticals Introduction and Business Overview
    Table 114. BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 115. BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Offerings
    Table 116. BioMarck Pharmaceuticals Recent Development
    Table 117. Key Raw Materials Lists
    Table 118. Raw Materials Key Suppliers Lists
    Table 119. Chronic Obstructive Pulmonary Disease Drugs Downstream Customers
    Table 120. Chronic Obstructive Pulmonary Disease Drugs Distributors List
    Table 121. Research Programs/Design for This Report
    Table 122. Key Data Information from Secondary Sources
    Table 123. Key Data Information from Primary Sources
List of Figures
    Figure 1. Chronic Obstructive Pulmonary Disease Drugs Product Picture
    Figure 2. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Chronic Obstructive Pulmonary Disease Drugs Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Chronic Obstructive Pulmonary Disease Drugs Report Years Considered
    Figure 7. Global Chronic Obstructive Pulmonary Disease Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Chronic Obstructive Pulmonary Disease Drugs Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Obstructive Pulmonary Disease Drugs Revenue in 2023
    Figure 10. Chronic Obstructive Pulmonary Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Inhalers Picture
    Figure 12. Nebulizers Picture
    Figure 13. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Chronic Obstructive Pulmonary Disease Drugs Price by Type (2019-2030) & (USD/Unit)
    Figure 18. Product Picture of Emphysema
    Figure 19. Product Picture of Chronic Bronchitis
    Figure 20. Product Picture of Refractory Asthma
    Figure 21. Product Picture of Others
    Figure 22. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Chronic Obstructive Pulmonary Disease Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 25. Global Chronic Obstructive Pulmonary Disease Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Chronic Obstructive Pulmonary Disease Drugs Price by Application (2019-2030) & (USD/Unit)
    Figure 27. North America Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Chronic Obstructive Pulmonary Disease Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Chronic Obstructive Pulmonary Disease Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Chronic Obstructive Pulmonary Disease Drugs Sales Volume (%), (2019-2030)
    Figure 39. United States Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Chronic Obstructive Pulmonary Disease Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Chronic Obstructive Pulmonary Disease Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Chronic Obstructive Pulmonary Disease Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 60. Chronic Obstructive Pulmonary Disease Drugs Industrial Chain
    Figure 61. Chronic Obstructive Pulmonary Disease Drugs Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Chronic Obstructive Pulmonary Diseases Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COPD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COPD Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disorder Market Research Report 2024
Asthma and COPD Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global COPD Drugs Market Research Report 2024
Global Asthma and COPD Devices Market Insights Forecast to 2030
Global Chronic Obstructive Pulmonary Disease COPD Treatment Market Insights Forecast to 2030
Global COPD Inhaler Market Research Report 2025
Drugs for Asthma and COPD Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disease Treatment Drug Market Research Report 2025
COPD Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global COPD and Asthma Devices Market Research Report 2024
Respiratory Diseases Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Emphysema Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Interventional Pulmonary Diseases Related to Chronic Obstructive Pulmonary Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Obstructive Pulmonary Disease Therapeutics Market Research Report 2024
Chronic Lung Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Respiratory Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti Asthmatics and COPD Drugs Market Research Report 2024

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions